D Corti Ortíz, P Rivera Garay, J Avilés Jasse, F Hidalgo Carmona, G MacMillan Soto, L F Coz Cañas, R Vargas Delaunoy, R Susaeta Saénz de San Pedro
Presentation of results obtained in 171 evaluable patients from a series of 181, presenting surface vesical cancer in Tis, Ta and T1 stages, treated with 3 different dosages of endovesical BCG as prophylaxis for tumour relapse: a) high dose, 100 to 120 mg, 72 patients; b) intermediate dose, 20 to 50 mg, 39 patients; and, c) minidose of 1 mg, 60 patients. Complications and adverse reactions were seen to be dose-dependent, also percentage of patients free of disease both after treatment and following addition of retreatment in several patients was similar in all the dosages used...
April 1993: Actas Urologicas Españolas